Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026
PALO ALTO, Calif., Oct. 19, 2026 /PRNewswire/ -- Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a poster at the European Society for Medical...
Covered in this story
Call it yourself
No calls on $MSS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Maison Solutions →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.